Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.
Mark Kozloff
Honoraria - Lilly
Rocio Carbonero
Honoraria - Lilly (I)
Tamara Nadal
No relevant relationships to disclose
Ivelina Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ann Cleverly
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Durisala Desaiah
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sada Pillay
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Al Blunt
Employment or Leadership Position - Covance
Stock Ownership - Covance
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Teresa Macarulla
No relevant relationships to disclose